US5554367A
(en)
*
|
1984-10-31 |
1996-09-10 |
Alcon Laboratories, Inc. |
Compositions for treatment of glaucoma
|
US5093126A
(en)
*
|
1987-09-26 |
1992-03-03 |
Alcon Laboratories, Inc. |
Glaucoma formulations comprising an anionic, polysulfonic acid polymer having mucomimetic properties and a polystyrene sulfonic polymer
|
US5192535A
(en)
*
|
1988-02-08 |
1993-03-09 |
Insite Vision Incorporated |
Ophthalmic suspensions
|
US5188826A
(en)
*
|
1988-02-08 |
1993-02-23 |
Insite Vision Incorporated |
Topical ophthalmic suspensions
|
US5461081A
(en)
*
|
1989-09-28 |
1995-10-24 |
Alcon Laboratories, Inc. |
Topical ophthalmic pharmaceutical vehicles
|
US5521222A
(en)
*
|
1989-09-28 |
1996-05-28 |
Alcon Laboratories, Inc. |
Topical ophthalmic pharmaceutical vehicles
|
US5660851A
(en)
*
|
1989-12-26 |
1997-08-26 |
Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem |
Ocular inserts
|
US5496471A
(en)
*
|
1990-01-08 |
1996-03-05 |
Ciba-Geigy Corporation |
Apparatus for removing components from solutions
|
US5124154A
(en)
*
|
1990-06-12 |
1992-06-23 |
Insite Vision Incorporated |
Aminosteroids for ophthalmic use
|
US5833665A
(en)
*
|
1990-06-14 |
1998-11-10 |
Integra Lifesciences I, Ltd. |
Polyurethane-biopolymer composite
|
US5252318A
(en)
*
|
1990-06-15 |
1993-10-12 |
Allergan, Inc. |
Reversible gelation compositions and methods of use
|
US5275820A
(en)
*
|
1990-12-27 |
1994-01-04 |
Allergan, Inc. |
Stable suspension formulations of bioerodible polymer matrix microparticles incorporating drug loaded ion exchange resin particles
|
CA2064160C
(en)
*
|
1991-03-27 |
1998-08-11 |
Paul J. T. Missel |
Use of combinations of gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
|
US5212162A
(en)
*
|
1991-03-27 |
1993-05-18 |
Alcon Laboratories, Inc. |
Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
|
US5182102A
(en)
*
|
1991-07-12 |
1993-01-26 |
Alcon Laboratories, Inc. |
Anti-glaucoma compositions
|
US5320839A
(en)
*
|
1991-10-11 |
1994-06-14 |
Alcon Laboratories, Inc. |
Topical ophthalmic compositions comprising 4-(3-substituted amino-2-hydroxypropoxy)-1,2,5-thiadiazoles and methods for their use
|
AU660735B2
(en)
*
|
1991-10-11 |
1995-07-06 |
Alcon Laboratories, Inc. |
Topical ophthalmic compositions comprising 4-(3-substituted amino-2-hydroxypropoxy)-1,2,5-thiadiazoles and methods for their use
|
JP2873530B2
(ja)
*
|
1991-12-13 |
1999-03-24 |
参天製薬株式会社 |
ニュートン型粘性を示すカルボキシビニルポリマー含有点眼液基剤
|
DE69320329T2
(de)
*
|
1992-02-21 |
1998-12-24 |
Alcon Lab Inc |
Topische Antiglaukoma Zusammensetzungen, enthaltend Karbonhydrasehemmer und Beta-Blocker
|
US5932572A
(en)
*
|
1992-02-21 |
1999-08-03 |
Alcon Laboratories, Inc. |
Topical anti-glaucoma compositions
|
US5296228A
(en)
*
|
1992-03-13 |
1994-03-22 |
Allergan, Inc. |
Compositions for controlled delivery of pharmaceutical compounds
|
TW205503B
(en)
*
|
1992-04-24 |
1993-05-11 |
Ciba Geigy Ag |
Apparatus for removing components from solutions
|
WO1993023082A1
(en)
*
|
1992-05-13 |
1993-11-25 |
Alcon Laboratories, Inc. |
Topical ophthalmic compositions comprising a combination of calcium antagonists with known antiglaucoma agents
|
AU666957B2
(en)
|
1992-08-28 |
1996-02-29 |
Alcon Laboratories, Inc. |
Use of certain anionic surfactants to enhance antimicrobial effectiveness of ophthalmic compositions
|
US5520920A
(en)
*
|
1992-08-28 |
1996-05-28 |
Alcon Laboratories, Inc. |
Use of certain anionic surfactants to enhance antimicrobial effectiveness of ophthalmic compositions
|
CA2146127C
(en)
*
|
1992-10-13 |
2000-06-13 |
Louis Desantis, Jr. |
Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma
|
US5340572A
(en)
*
|
1993-02-08 |
1994-08-23 |
Insite Vision Incorporated |
Alkaline ophthalmic suspensions
|
AU7668894A
(en)
*
|
1993-08-13 |
1995-03-14 |
Vitaphore Corporation |
Hydrogel-based microsphere drug delivery systems
|
CN1129400A
(zh)
*
|
1994-05-06 |
1996-08-21 |
阿尔康实验室公司 |
维生素e生育酚衍生物在眼科组合物中的应用
|
US5662919A
(en)
*
|
1994-11-21 |
1997-09-02 |
Alcon Laboratories, Inc. |
Sulfated polyvinyl alcohol polymers to stabilize pharmaceutical drug compounds
|
US5972326A
(en)
*
|
1995-04-18 |
1999-10-26 |
Galin; Miles A. |
Controlled release of pharmaceuticals in the anterior chamber of the eye
|
US5612027A
(en)
*
|
1995-04-18 |
1997-03-18 |
Galin; Miles A. |
Controlled release of miotic and mydriatic drugs in the anterior chamber
|
US6172054B1
(en)
|
1995-06-15 |
2001-01-09 |
Alcon Laboratories, Inc. |
Combination therapy for lowering and controlling intraocular pressure
|
US6441047B2
(en)
|
1995-11-17 |
2002-08-27 |
Alcon Manufacturing Ltd.. |
Combination therapy for treating glaucoma
|
CA2237898A1
(en)
*
|
1995-11-17 |
1997-05-29 |
Louis Desantis Jr. |
Combination therapy for treating glaucoma
|
KR100452715B1
(ko)
|
1995-12-21 |
2004-12-17 |
알콘 래보레이토리스, 인코퍼레이티드 |
녹내장및안구국소빈혈을치료하기위한특정이소퀴놀린술포닐화합물의용도
|
US6159458A
(en)
*
|
1997-11-04 |
2000-12-12 |
Insite Vision |
Sustained release ophthalmic compositions containing water soluble medicaments
|
AU761785B2
(en)
*
|
1998-09-25 |
2003-06-12 |
Alcon Laboratories, Inc. |
Sustained release, and comfortable ophthalmic composition and method for ocular therapy
|
US6444710B1
(en)
|
1998-10-27 |
2002-09-03 |
Alcon Manufacturing, Ltd. |
Use of certain fatty acid/amino acid soaps to enhance antimicrobial effectiveness of topically administrable pharmaceutical compositions
|
BR9914813A
(pt)
|
1998-10-27 |
2001-07-03 |
Alcon Lab Inc |
Sistema conservante para composições farmacêuticas administráveis topicamente
|
US6146622A
(en)
*
|
1998-10-27 |
2000-11-14 |
Alcon Laboratories, Inc. |
Use of certain anionic amino acid based surfactants to enhance antimicrobial effectiveness of topically administrable pharmaceutical compositions
|
DK1124535T3
(da)
|
1998-10-27 |
2003-01-06 |
Alcon Lab Inc |
Konserverende system til topisk indgivelige farmaceutiske præparater indeholdende en fedtsyre/aminosyresæbe
|
US6258350B1
(en)
|
1999-01-20 |
2001-07-10 |
Alcon Manufacturing, Ltd. |
Sustained release ophthalmic formulation
|
KR100753184B1
(ko)
|
1999-01-25 |
2007-08-30 |
내셔날 쥬이쉬 메디칼 앤드 리서치 센터 |
치환된 포르피린
|
AU4338700A
(en)
*
|
1999-05-12 |
2000-12-05 |
Alcon Laboratories, Inc. |
Use of polymeric adsorbents in pharmaceutical dosage forms
|
US6730691B1
(en)
*
|
2000-02-10 |
2004-05-04 |
Miles A. Galin |
Uses of alpha adrenergic blocking agents
|
DE10115282B4
(de)
*
|
2000-03-29 |
2006-03-02 |
Hitachi, Ltd. |
Einlaßluftsteuervorrichtung und Brennkraftmaschine, in der sie montiert ist
|
PE20020578A1
(es)
|
2000-10-10 |
2002-08-14 |
Upjohn Co |
Una composicion de antibiotico topico para el tratamiento de infecciones oculares
|
US20040121947A1
(en)
*
|
2000-12-28 |
2004-06-24 |
Oklahoma Medical Research Foundation |
Compounds which inhibit beta-secretase activity and methods of use thereof
|
US20020176842A1
(en)
*
|
2001-04-09 |
2002-11-28 |
Lyn Hughes |
Extended release of active ingredients
|
JP2005508864A
(ja)
*
|
2001-06-01 |
2005-04-07 |
ナショナル・ジュウィッシュ・メディカル・アンド・リサーチ・センター |
糖尿病の治療、または移植術における使用、または免疫寛容の誘導のためのオキシダントスカベンジャー
|
US6743439B1
(en)
|
2001-06-27 |
2004-06-01 |
Alcon, Inc. |
Ophthalmic compositions containing copolymers of sulfonated styrene and maleic anhydride
|
US20030220376A1
(en)
*
|
2001-08-10 |
2003-11-27 |
Pharmacia Corporation |
Methods for treating carbonic anhydrase mediated disorders
|
US20040067992A1
(en)
*
|
2001-08-10 |
2004-04-08 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia
|
US20030100594A1
(en)
*
|
2001-08-10 |
2003-05-29 |
Pharmacia Corporation |
Carbonic anhydrase inhibitor
|
WO2003020242A1
(en)
*
|
2001-08-29 |
2003-03-13 |
Srl Technologies, Inc. |
Sustained release preparations
|
JP4547152B2
(ja)
*
|
2001-10-23 |
2010-09-22 |
オクラホマ メディカル リサーチ ファウンデーション |
β−セクレターゼ阻害剤および使用方法
|
US20060234944A1
(en)
*
|
2001-10-23 |
2006-10-19 |
Oklahoma Medical Reseach Foundation |
Beta-secretase inhibitors and methods of use
|
US7001615B1
(en)
|
2001-12-07 |
2006-02-21 |
Alcon, Inc. |
Sustained release ophthalmic, otic and nasal suspension
|
RU2005102604A
(ru)
*
|
2002-07-03 |
2005-09-10 |
Перикор Сайенс, Инк. (Us) |
Композиция гиалуроновой кислоты и способы применения
|
US20050147584A1
(en)
*
|
2004-01-05 |
2005-07-07 |
Allergan, Inc. |
Compositions and methods comprising memantine and polyanionic polymers
|
US20050031652A1
(en)
*
|
2003-02-25 |
2005-02-10 |
Allergan, Inc. |
Compositions and methods comprising memantine and polyanionic polymers
|
US20050277698A1
(en)
*
|
2004-01-05 |
2005-12-15 |
Hughes Patrick M |
Memantine delivery to the back of the eye
|
US20050265955A1
(en)
*
|
2004-05-28 |
2005-12-01 |
Mallinckrodt Inc. |
Sustained release preparations
|
US20080207527A1
(en)
*
|
2004-09-17 |
2008-08-28 |
Comentis, Inc. |
Bicyclic Compounds Which Inhibit Beta-Secretase Activity and Methods of Use Thereof
|
US7659289B2
(en)
*
|
2004-09-17 |
2010-02-09 |
Comentis, Inc. |
Hydroxyethylene-based β-secretase inhibitors and use thereof
|
WO2006062731A1
(en)
*
|
2004-11-19 |
2006-06-15 |
University Of North Texas Health Science Center At Fort Worth |
Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye
|
JP2008520744A
(ja)
*
|
2004-11-19 |
2008-06-19 |
ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア |
抗炎症性ピラゾロピリミジン
|
CA2604291A1
(en)
*
|
2005-04-08 |
2006-10-19 |
Comentis, Inc. |
Compounds which inhibit beta-secretase activity and methods of use thereof
|
US20070077302A1
(en)
*
|
2005-09-30 |
2007-04-05 |
Azaam Alli |
Methods for stabilizing ophthalmic compositions
|
EP1957986B1
(de)
*
|
2005-11-22 |
2017-05-24 |
McGill University |
Frühgene mit reguliertem zwischenaugendruck und verwendungen davon
|
EP2038272B8
(de)
|
2006-06-30 |
2013-10-23 |
Sunesis Pharmaceuticals, Inc. |
Pyridinonyl-pdk1-hemmer
|
US8158667B2
(en)
*
|
2006-08-21 |
2012-04-17 |
Kador Peter F |
Topical treatment of cataracts in dogs
|
WO2008070132A2
(en)
*
|
2006-12-05 |
2008-06-12 |
The Royal Institution For The Advancement Of Learning/ Mcgill University |
Methods of use of trk receptor modulators
|
AU2011253937B2
(en)
*
|
2006-12-05 |
2012-09-27 |
The Royal Institution For The Advancement Of Learning/ Mcgill University |
Methods of use of TRK receptor modulators
|
US8968786B2
(en)
|
2007-06-22 |
2015-03-03 |
Board Of Regents, The University Of Texas System |
Formation of stable submicron peptide or protein particles by thin film freezing
|
EP2178837A2
(de)
*
|
2007-07-26 |
2010-04-28 |
Comentis, Inc. |
Isophthalamidderivate als hemmer der beta-sekretase-aktivität
|
CA2699787A1
(en)
*
|
2007-09-24 |
2009-04-02 |
Comentis, Inc. |
(3-hydroxy-4-amino-butan-2-yl)-3-(2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating
|
ES2600469T3
(es)
|
2008-05-23 |
2017-02-09 |
National Jewish Health |
Un compuesto para su uso en el tratamiento de lesiones asociadas con la exposición al gas fosgeno o al gas de cloro
|
US20110224223A1
(en)
|
2008-07-08 |
2011-09-15 |
The Regents Of The University Of California, A California Corporation |
MTOR Modulators and Uses Thereof
|
WO2010011684A2
(en)
*
|
2008-07-21 |
2010-01-28 |
The Regents Of The University Of California |
Prodrug and fluoregenic compositions and methods for using the same
|
WO2010031056A2
(en)
|
2008-09-15 |
2010-03-18 |
The Regents Of The University Of California |
Methods and compositions for modulating ire1, src, and abl activity
|
AU2010220061A1
(en)
*
|
2009-02-20 |
2010-09-10 |
Micro Labs Limited |
Storage stable prostaglandin product
|
ES2608670T3
(es)
|
2009-08-17 |
2017-04-12 |
Memorial Sloan-Kettering Cancer Center |
Derivados de 2-(pirimidin-5-il)-tiopirimidina como moduladores de Hsp70 y Hsc70 para el tratamiento de trastornos proliferativos
|
HUE043522T2
(hu)
|
2009-09-04 |
2019-08-28 |
Biogen Ma Inc |
Bruton tirozinkináz inhibitorok
|
EP2485589A4
(de)
|
2009-09-04 |
2013-02-06 |
Biogen Idec Inc |
Heteroaryl-btk-hemmer
|
CN102665718B
(zh)
|
2009-10-06 |
2016-03-09 |
米伦纽姆医药公司 |
可用作pdk1抑制剂的杂环化合物
|
WO2011047384A2
(en)
|
2009-10-16 |
2011-04-21 |
The Regents Of The University Of California |
Methods of inhibiting ire1
|
EP2493465B1
(de)
|
2009-10-26 |
2014-10-22 |
Sephoris Pharmaceuticals, LLC |
Behandlung von Sonnenbrand mit Schmerzmitteln und Antihistaminika
|
BR112012011528A2
(pt)
|
2009-11-16 |
2019-09-24 |
Univ California |
métodos para inibir uma proteína quinase e para tratar uma doença associada com atividade de quinase, e, composto
|
HUE027199T2
(en)
|
2009-12-10 |
2016-08-29 |
Univ California |
Amyloid binding agents
|
AU2011238616B2
(en)
|
2010-03-30 |
2016-08-04 |
Verseon Corporation |
Multisubstituted aromatic compounds as inhibitors of thrombin
|
WO2012058645A1
(en)
|
2010-10-29 |
2012-05-03 |
Biogen Idec Ma Inc. |
Heterocyclic tyrosine kinase inhibitors
|
CN103459368B
(zh)
|
2011-02-14 |
2016-06-08 |
阿勒根公司 |
比马前列素组合物的酯衍生物和方法
|
KR102052670B1
(ko)
|
2011-05-17 |
2019-12-06 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
키나아제 저해제
|
WO2012158795A1
(en)
|
2011-05-17 |
2012-11-22 |
Principia Biopharma Inc. |
Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
|
WO2012158764A1
(en)
|
2011-05-17 |
2012-11-22 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
EP2714069A4
(de)
|
2011-05-25 |
2015-06-24 |
Amylin Pharmaceuticals Llc |
Langzeitkonjugate mit zwei hormonen
|
WO2013006569A2
(en)
|
2011-07-01 |
2013-01-10 |
The Regents Of The University Of California |
Herpes virus vaccine and methods of use
|
MX370814B
(es)
|
2011-09-02 |
2020-01-08 |
Univ California |
Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
|
US9073851B2
(en)
|
2011-10-28 |
2015-07-07 |
Board Of Regents, The University Of Texas System |
Compositions and methods for treating cancer
|
EP2836482B1
(de)
|
2012-04-10 |
2019-12-25 |
The Regents of The University of California |
Zusammensetzungen und verfahren zur behandlung von krebs
|
US9353087B2
(en)
|
2012-06-08 |
2016-05-31 |
Biogen Ma Inc. |
Inhibitors of Bruton's tyrosine kinase
|
AR091273A1
(es)
|
2012-06-08 |
2015-01-21 |
Biogen Idec Inc |
Inhibidores de pirimidinil tirosina quinasa
|
CA2913736A1
(en)
|
2012-06-11 |
2013-12-19 |
The Regents Of The University Of California |
Compounds and methods of treating cancer
|
US9090595B2
(en)
|
2012-08-27 |
2015-07-28 |
Allergan, Inc. |
Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
|
ES2711425T3
(es)
|
2012-08-27 |
2019-05-03 |
Allergan Inc |
Espesamiento de la córnea central reducido mediante el uso de profármacos de éster hidrófilos de beta-clorociclopentanos
|
MX361815B
(es)
|
2012-09-10 |
2018-12-17 |
Principia Biopharma Inc |
Compuestos pirazolopirimidinicos como inhibidores de cinasas.
|
RU2015115631A
(ru)
|
2012-09-26 |
2016-11-20 |
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния |
Модулирование ire1
|
CN108440571B
(zh)
|
2012-10-22 |
2022-11-04 |
希望之城 |
Etp衍生物
|
US9364462B2
(en)
|
2012-10-30 |
2016-06-14 |
The Regents Of The University Of California |
Alpha-1-adrenergic receptor agonist therapy
|
AU2014214561C1
(en)
|
2013-02-11 |
2019-01-17 |
Mitokinin, Inc. |
Compositions and methods for treating neurodegenerative diseases
|
WO2014165263A1
(en)
|
2013-03-12 |
2014-10-09 |
The Regents Of The University Of California, A California Corporation |
Gamma-secretase modulators
|
WO2014143591A1
(en)
|
2013-03-12 |
2014-09-18 |
Allergan, Inc. |
Inhibition of neovascularization by simultaneous inhibition of prostanoid ip and ep4 receptors
|
WO2014143592A1
(en)
|
2013-03-12 |
2014-09-18 |
Allergan, Inc. |
Inhibition of neovascularization by inhibition of prostanoid ip receptors
|
AU2014236356A1
(en)
|
2013-03-14 |
2015-09-24 |
The Regents Of The University Of California |
Thiosaccharide mucolytic agents
|
AU2014236370C1
(en)
|
2013-03-14 |
2019-01-17 |
City Of Hope |
5-bromo-indirubins
|
WO2014165307A2
(en)
|
2013-03-14 |
2014-10-09 |
The Regents Of The University Of California |
Modulation of k2p channels
|
AU2014228307A1
(en)
|
2013-03-15 |
2015-09-10 |
Allergan, Inc. |
Bimatoprost for enhancement of leptin production
|
WO2014143643A1
(en)
|
2013-03-15 |
2014-09-18 |
The Regents Of The University Of California, A California Corporation |
Acyclic nucleoside phosphonate diesters
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
MX2015011567A
(es)
|
2013-03-15 |
2016-04-25 |
Verseon Corp |
Halogeno-pirazoles como inhibidores de trombina.
|
WO2014146111A2
(en)
|
2013-03-15 |
2014-09-18 |
The Regents Of The University Of California |
Analgesic compounds and methods of use
|
EP3421036B8
(de)
|
2013-03-15 |
2020-12-30 |
Verseon International Corporation |
Multisubstituierte aromatische verbindungen als serinproteaseinhibitoren
|
JP6806562B2
(ja)
|
2013-03-15 |
2021-01-06 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
eIF2α経路の調節因子
|
US8957080B2
(en)
|
2013-04-09 |
2015-02-17 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
WO2014190207A1
(en)
|
2013-05-22 |
2014-11-27 |
The Regents Of The University Of California |
Aurora kinase inhibitors
|
US9795691B2
(en)
|
2013-06-24 |
2017-10-24 |
City Of Hope |
Chemically-linked nanoparticles
|
EP3022207A4
(de)
|
2013-07-15 |
2016-12-07 |
Univ Texas |
Verbindungen und verfahren zur behandlung von krebs, neurologischen erkrankungen, ethanolentzug, angstzuständen, depression und neuropathischen schmerzen
|
SI3035926T1
(sl)
|
2013-08-19 |
2020-11-30 |
The Regents Of The University Of California |
Spojine in postopki za zdravljenje epileptičnih motenj
|
CN105979941A
(zh)
|
2013-08-20 |
2016-09-28 |
希望之城 |
用于治疗癌症的hdac8抑制剂
|
WO2015031799A1
(en)
|
2013-08-30 |
2015-03-05 |
The Regents Of The University Of California, A California Corporation |
Scintillator nanocrystal-containing compositions and methods for their use
|
JO3805B1
(ar)
|
2013-10-10 |
2021-01-31 |
Araxes Pharma Llc |
مثبطات كراس جي12سي
|
CA2932608C
(en)
|
2013-12-11 |
2023-02-14 |
Biogen Ma Inc. |
Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
|
EP3080122B1
(de)
|
2013-12-11 |
2018-10-31 |
Biogen MA Inc. |
Zur behandlung von erkrankungen des menschen in der onkologie, neurologie und immunologie geeignete biarylverbindungen
|
WO2015138039A1
(en)
|
2013-12-23 |
2015-09-17 |
Memorial Sloan-Kettering Cancer Center |
Methods and reagents for radiolabeling
|
WO2015116856A2
(en)
|
2014-01-29 |
2015-08-06 |
City Of Hope |
Farnesoid x receptor antagonists
|
US10167286B2
(en)
|
2014-02-11 |
2019-01-01 |
Mitokinin, Inc. |
Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
|
WO2015123595A1
(en)
|
2014-02-14 |
2015-08-20 |
The Regents Of The University Of California |
Cyclic peroxides as prodrugs for selective delivery of agents
|
EP3107906B1
(de)
|
2014-02-20 |
2018-12-05 |
Allergan, Inc. |
Reduzierung der verdickung der zentralen hornhaut durch verwendung hydrophiler ester-prodrugs von beta-chlorcyclopentanen
|
SG11201606858RA
(en)
|
2014-02-21 |
2016-09-29 |
Principia Biopharma Inc |
Salts and solid form of a btk inhibitor
|
US20150259288A1
(en)
|
2014-03-14 |
2015-09-17 |
City Of Hope |
5-bromo-indirubins
|
EP3128842B1
(de)
|
2014-03-26 |
2023-07-26 |
City of Hope |
Behandlung von brca1-defektem krebs oder -resistentem krebs
|
EP3988540A1
(de)
|
2014-04-07 |
2022-04-27 |
The Regents of the University of California |
Inhibitoren des enzyms der fettsäureamidhydrolase (faah) mit verbesserter oraler bioverfügbarkeit und deren verwendung als arzneimittel
|
TWI699204B
(zh)
|
2014-05-13 |
2020-07-21 |
美國紀念斯隆 凱特琳癌症中心 |
Hsp70調節子及其製造及使用方法
|
WO2015183794A1
(en)
|
2014-05-27 |
2015-12-03 |
City Of Hope |
Tgr5 agonist complexes for treating diabetes and cancer
|
US10414814B2
(en)
|
2014-07-03 |
2019-09-17 |
City Of Hope |
Tumor-selective CTLA-4 antagonists
|
EP3954362A1
(de)
|
2014-07-28 |
2022-02-16 |
Sun Pharma Advanced Research Company Ltd |
Verfahren zur erhöhung der bioverfügbarkeit und/oder zur verlängerung der ophthalmischen wirkung eines arzneimittels
|
US11072681B2
(en)
|
2014-07-28 |
2021-07-27 |
The Regents Of The University Of California |
Compositions and methods of making polymerizing nucleic acids
|
WO2016023036A1
(en)
|
2014-08-08 |
2016-02-11 |
The Regents Of The University Of California |
High density peptide polymers
|
WO2016040806A1
(en)
|
2014-09-11 |
2016-03-17 |
The Regents Of The University Of California |
mTORC1 INHIBITORS
|
SI3194411T1
(sl)
|
2014-09-15 |
2022-07-29 |
The Regents Of The University Of California |
Nukleotidni analogi
|
JP2017528486A
(ja)
|
2014-09-17 |
2017-09-28 |
ヴァーセオン コーポレイション |
セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
EP3197870B1
(de)
|
2014-09-25 |
2020-08-19 |
Araxes Pharma LLC |
Inhibitoren von g12c mutierten kras proteinen
|
US10011600B2
(en)
|
2014-09-25 |
2018-07-03 |
Araxes Pharma Llc |
Methods and compositions for inhibition of Ras
|
AU2015327817B2
(en)
|
2014-10-02 |
2020-04-23 |
Allergan, Inc. |
Ester prodrugs of gamma-lactams and their use
|
NZ733130A
(en)
|
2014-12-15 |
2018-09-28 |
Univ Johns Hopkins |
Sunitinib formulations and methods for use thereof in treatment of ocular disorders
|
MX2017007973A
(es)
|
2014-12-18 |
2018-02-09 |
Principia Biopharma Inc |
Tratamiento de penfigo.
|
WO2016115275A1
(en)
|
2015-01-13 |
2016-07-21 |
City Of Hope |
Ctla4-binding protein peptide-linker masks
|
MX2017009272A
(es)
|
2015-01-16 |
2018-04-11 |
|
Anticuerpos que penetran en células.
|
US10227333B2
(en)
|
2015-02-11 |
2019-03-12 |
Curtana Pharmaceuticals, Inc. |
Inhibition of OLIG2 activity
|
SI3261640T1
(sl)
|
2015-02-25 |
2022-10-28 |
The Regents Of The University Of California |
5HT agonisti za zdravljenje epilepsijskih motenj
|
JP2018508513A
(ja)
|
2015-02-27 |
2018-03-29 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
軟骨若返りを可能とする小分子
|
JP2018510138A
(ja)
|
2015-02-27 |
2018-04-12 |
カーテナ ファーマシューティカルズ,インク. |
Olig2活性の阻害
|
KR20170122767A
(ko)
|
2015-02-27 |
2017-11-06 |
베르선 코포레이션 |
세린 프로테아제 저해제로서의 치환된 피라졸 화합물
|
JP6976854B2
(ja)
|
2015-03-30 |
2021-12-08 |
シティ・オブ・ホープCity of Hope |
機械的にかみ合った複合体
|
EA201792214A1
(ru)
|
2015-04-10 |
2018-01-31 |
Араксис Фарма Ллк |
Соединения замещенного хиназолина
|
ES2856880T3
(es)
|
2015-04-15 |
2021-09-28 |
Araxes Pharma Llc |
Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos
|
CA2982890C
(en)
|
2015-04-17 |
2023-08-22 |
Ludwig Institute For Cancer Research Ltd |
Plk4 inhibitors
|
EP3286214B1
(de)
|
2015-04-24 |
2023-12-06 |
The Regents of the University of California |
Modulatoren der ror1-ror2-bindung
|
CA2986030A1
(en)
|
2015-05-15 |
2016-11-24 |
City Of Hope |
Chimeric antigen receptor compositions
|
RU2724955C2
(ru)
*
|
2015-05-21 |
2020-06-29 |
Офтэлмис Монако |
Офтальмологическая композиция, содержащая липоевую кислоту и мукомиметический полимер
|
US10787664B2
(en)
|
2015-05-26 |
2020-09-29 |
City Of Hope |
Compounds of chemically modified oligonucleotides and methods of use thereof
|
EP3307732A1
(de)
|
2015-06-10 |
2018-04-18 |
Biogen MA Inc. |
Formen und zusammensetzungen von biarylinhibitoren der bruton-tyrosinkinase
|
US10765696B2
(en)
|
2015-06-10 |
2020-09-08 |
City Of Hope |
Compositions of and methods of treatment with zwitterionic polysaccharide
|
WO2016210165A1
(en)
|
2015-06-24 |
2016-12-29 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
JP7073109B2
(ja)
|
2015-07-02 |
2022-05-23 |
シティ・オブ・ホープ |
ホスホロチオエート化オリゴデオキシヌクレオチドを含む化合物及び組成物、ならびにそれらの使用法
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
CN108135958B
(zh)
|
2015-08-06 |
2022-03-04 |
希望之城 |
细胞穿透蛋白-抗体缀合物及其使用方法
|
US11136301B2
(en)
|
2015-08-31 |
2021-10-05 |
The Regents of the University of California, A California Corporation et al. |
Broad spectrum antiviral compounds and uses thereof
|
WO2017040982A1
(en)
|
2015-09-02 |
2017-03-09 |
The Regents Of The University Of California |
Her3 ligands and uses thereof
|
US10428048B2
(en)
|
2015-09-04 |
2019-10-01 |
City Of Hope |
Androgen receptor antagonists
|
CA2998294C
(en)
|
2015-09-25 |
2023-09-12 |
Ludwig Institute For Cancer Research Ltd |
3-hydroxy-quinazoline-2,4-dione derivatives and their use as nuclease modulators
|
EP3356354A1
(de)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitoren von kras-g12c-mutanten proteinen
|
WO2017058728A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
EP3356349A1
(de)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitoren von kras-g12c-mutanten proteinen
|
US10882847B2
(en)
|
2015-09-28 |
2021-01-05 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
WO2017058902A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
EP3356347A1
(de)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitoren von kras-g12c-mutanten proteinen
|
EP3356351A1
(de)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitoren von kras-g12c-mutanten proteinen
|
JP7038045B2
(ja)
|
2015-10-15 |
2022-03-17 |
シティ・オブ・ホープ |
ホスホロチオエート化オリゴデオキシヌクレオチドを含む化合物及び組成物、ならびにその使用方法
|
WO2017070256A2
(en)
|
2015-10-19 |
2017-04-27 |
Araxes Pharma Llc |
Method for screening inhibitors of ras
|
BR112018008103A2
(pt)
|
2015-10-23 |
2018-11-06 |
Erx Pharmaceuticals, Inc. |
análogos de celastrol
|
AU2016342352B2
(en)
|
2015-10-23 |
2022-06-02 |
Sunesis Pharmaceuticals, Inc. |
Heterocyclic PDK1 inhibitors for use to treat cancer
|
US11058700B2
(en)
|
2015-10-28 |
2021-07-13 |
City Of Hope |
Macrocyclic lactones and uses thereof as modulators of purinergic receptors
|
CN108367079B
(zh)
|
2015-11-12 |
2022-11-22 |
灰色视觉公司 |
用于治疗的聚集性微粒
|
AU2016355433C1
(en)
|
2015-11-16 |
2021-12-16 |
Araxes Pharma Llc |
2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
|
WO2017100546A1
(en)
|
2015-12-09 |
2017-06-15 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
CN112274649A
(zh)
|
2015-12-10 |
2021-01-29 |
希望之城 |
细胞穿透花青偶联抗体
|
CA3009534A1
(en)
|
2015-12-24 |
2017-06-29 |
The Regents Of The University Of California |
3-aryl-quinoxalinone derivatives and use thereof as cftr regulators
|
PL3394040T3
(pl)
|
2015-12-24 |
2022-05-02 |
The Regents Of The University Of California |
Regulatory cftr i sposoby ich zastosowania
|
CN108697690B
(zh)
|
2016-01-05 |
2022-01-14 |
加利福尼亚大学董事会 |
苯并噻唑两亲物
|
US10519442B2
(en)
|
2016-02-11 |
2019-12-31 |
City Of Hope |
Twist signaling inhibitor compositions and methods of using the same
|
WO2017161344A1
(en)
|
2016-03-17 |
2017-09-21 |
The Regants Of The University Of California |
Compositions and methods for treating parasitic diseases
|
WO2017172979A1
(en)
|
2016-03-30 |
2017-10-05 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
PL3458448T3
(pl)
|
2016-04-25 |
2021-12-06 |
Forma Therapeutics, Inc. |
Inhibitory fasn do zastosowania w leczeniu niealkoholowego stłuszczeniowego zapalenia wątroby
|
WO2017190107A1
(en)
|
2016-04-29 |
2017-11-02 |
Board Of Regents, The University Of Texas System |
Sigma receptor binders
|
TWI763668B
(zh)
|
2016-05-05 |
2022-05-11 |
美商嘉來克生命科學有限責任公司 |
整合應激途徑之調節劑
|
TW201808914A
(zh)
|
2016-05-05 |
2018-03-16 |
嘉來克生命科學有限責任公司 |
整合應激途徑之調節劑
|
JP6715957B2
(ja)
|
2016-05-12 |
2020-07-01 |
アナコール・ファーマシューティカルズ・インコーポレーテッド |
オキサボロールエステル及びその使用
|
WO2017205611A1
(en)
|
2016-05-26 |
2017-11-30 |
The Regents Of The University Of California |
Estrogen receptor modulator combinations
|
IL263815B
(en)
|
2016-06-29 |
2022-07-01 |
Principia Biopharma Inc |
Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(Oxtan-3-yl)piperazin-1-yl)pent-2-ananitrile
|
US11045493B2
(en)
|
2016-07-11 |
2021-06-29 |
The Regents Of The University Of California |
Synthetic melanin nanoparticles and uses thereof
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
MX2019000884A
(es)
|
2016-07-21 |
2019-09-04 |
Biogen Ma Inc |
Formas de succinato y composiciones de inhibidores de la tirosina cinasa de bruton.
|
TWI817929B
(zh)
|
2016-07-29 |
2023-10-11 |
美商瑞佩特治療公司 |
趨化介素受體調節劑及其用途
|
US11254667B2
(en)
|
2016-08-17 |
2022-02-22 |
Children's Hospital Medical Center |
Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors
|
US11542261B2
(en)
|
2016-08-17 |
2023-01-03 |
Children's Hospital Medical Center |
Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors
|
WO2018039612A1
(en)
|
2016-08-26 |
2018-03-01 |
The Regents Of The University Of California |
Compositions and methods for promoting hair growth with mpc1 inhibitors
|
WO2018053035A1
(en)
|
2016-09-13 |
2018-03-22 |
The Jackson Laboratory |
Targeted dna demethylation and methylation
|
EP3512520B1
(de)
|
2016-09-15 |
2023-06-21 |
City of Hope |
Dithio-derivate von epidithiodiketopiperazine (etp)
|
US10849955B2
(en)
|
2016-09-28 |
2020-12-01 |
City Of Hope |
Methods of treating pancreatic cancer using GPCR antagonists
|
EP3519402A1
(de)
|
2016-09-29 |
2019-08-07 |
Araxes Pharma LLC |
Inhibitoren von kras-g12c-mutanten proteinen
|
JP2019534260A
(ja)
|
2016-10-07 |
2019-11-28 |
アラクセス ファーマ エルエルシー |
Rasの阻害剤としての複素環式化合物およびその使用方法
|
US10646540B2
(en)
|
2016-11-18 |
2020-05-12 |
City Of Hope |
Peptide inhibitors of twist
|
RU2019121922A
(ru)
|
2016-12-15 |
2021-01-18 |
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния |
Композиции и способы лечения рака
|
EP3573954A1
(de)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fusionierte bicyclische benzoheteroaromatische verbindungen und verfahren zur verwendung davon
|
US11279689B2
(en)
|
2017-01-26 |
2022-03-22 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
|
EP3573964A1
(de)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Benzothiophen- und benzothiazolverbindungen und verfahren zur verwendung davon
|
WO2018140514A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
|
CN110382482A
(zh)
|
2017-01-26 |
2019-10-25 |
亚瑞克西斯制药公司 |
稠合的杂-杂二环化合物及其使用方法
|
CN110662543A
(zh)
|
2017-03-23 |
2020-01-07 |
灰色视觉公司 |
用于治疗眼部疾病的药物和组合物
|
CA3057875A1
(en)
|
2017-05-10 |
2018-11-15 |
Graybug Vision, Inc. |
Extended release microparticles and suspensions thereof for medical therapy
|
TW201906832A
(zh)
|
2017-05-25 |
2019-02-16 |
美商亞瑞克西斯製藥公司 |
用於癌症治療之化合物及其使用方法
|
US11639346B2
(en)
|
2017-05-25 |
2023-05-02 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
|
BR112019024674A2
(pt)
|
2017-05-25 |
2020-06-16 |
Araxes Pharma Llc |
Inibidores covalentes da kras
|
AU2018290225A1
(en)
|
2017-06-21 |
2020-01-23 |
Mitokinin, Inc. |
Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
|
WO2019006371A1
(en)
|
2017-06-30 |
2019-01-03 |
City Of Hope |
COMPOSITIONS AND METHODS FOR MODULATING MACROPHAGE ACTIVITY
|
US11389460B2
(en)
|
2017-09-15 |
2022-07-19 |
City Of Hope |
Methods and compositions for treating endometrial cancer
|
US20200354452A1
(en)
|
2017-09-29 |
2020-11-12 |
City Of Hope |
Cars and bispecific antibodies for treatment of mantle cell lymphoma
|
MA50664A
(fr)
|
2017-09-29 |
2020-08-05 |
Genentech Inc |
Complexes d'antibiotiques peptidiques et leurs méthodes d'utilisation
|
WO2019070917A1
(en)
|
2017-10-03 |
2019-04-11 |
The Schepens Eye Research Institute, Inc. |
COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE DEGENERATION OF RETINAL PIGMENT EPITHELIUM AND METHODS USING SAME
|
EP3694860A1
(de)
|
2017-10-10 |
2020-08-19 |
Syros Pharmaceuticals, Inc. |
Pyrrolotriazinverbindungen und verfahren zur hemmung von tam-kinasen
|
US11618780B2
(en)
|
2017-10-20 |
2023-04-04 |
City Of Hope |
Composition and method for activating latent human immunodeficiency virus (HIV)
|
CN112218869A
(zh)
|
2017-11-02 |
2021-01-12 |
卡里科生命科学有限责任公司 |
整合应激通路的调节剂
|
IL274406B2
(en)
|
2017-11-02 |
2024-04-01 |
Calico Life Sciences Llc |
Combined pressure pathway modulators
|
UY37957A
(es)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
Moduladores de la vía de estrés integrada
|
UY37956A
(es)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
Moduladores de la vía de estrés integrada
|
MX2020004557A
(es)
|
2017-11-02 |
2020-10-05 |
Calico Life Sciences Llc |
Moduladores de la vía de estrés integrada.
|
AU2018360855B2
(en)
|
2017-11-02 |
2023-04-06 |
Abbvie Inc. |
Modulators of the integrated stress pathway
|
UY37958A
(es)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
Moduladores de la vía de estrés integrada
|
MX2020004519A
(es)
|
2017-11-02 |
2020-11-09 |
Calico Life Sciences Llc |
Moduladores de la vía de estrés integrada.
|
EP3704098B1
(de)
|
2017-11-02 |
2024-01-24 |
Calico Life Sciences LLC |
Modulatoren eines integrierten spannungswegs
|
IL274444B1
(en)
|
2017-11-06 |
2024-02-01 |
Rapt Therapeutics Inc |
Chemokine receptor modulators for the treatment of Epstein-Barr virus-positive cancer
|
MA51052A
(fr)
|
2017-12-07 |
2021-04-21 |
Amplyx Pharmaceuticals Inc |
Agents antifongiques dérivés de pyridine substitués par un hétérocycle
|
US11939575B2
(en)
|
2017-12-19 |
2024-03-26 |
City Of Hope |
Modified tracrRNAs gRNAs, and uses thereof
|
AU2019209470A1
(en)
|
2018-01-16 |
2020-08-13 |
Syros Pharmaceuticals, Inc. |
Inhibitors of cyclin-dependent kinase 7 (CDK7)
|
CA3088529A1
(en)
|
2018-01-16 |
2019-07-25 |
Syros Pharmaceuticals, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
MX2020007812A
(es)
|
2018-01-26 |
2020-11-24 |
Rapt Therapeutics Inc |
Moduladores del receptor de quimiocina y usos de los mismos.
|
KR20200143376A
(ko)
|
2018-03-13 |
2020-12-23 |
샤이어 휴먼 지네틱 테라피즈 인크. |
혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도
|
EP3784233A4
(de)
|
2018-04-27 |
2022-03-02 |
Spruce Biosciences, Inc. |
Verfahren zur behandlung von hoden-und eierstock-nebennierentumoren
|
JP7381492B2
(ja)
|
2018-05-01 |
2023-11-15 |
レヴォリューション・メディスンズ,インコーポレイテッド |
Mtor阻害剤としてのc26-連結ラパマイシン類似体
|
CR20200578A
(es)
|
2018-05-01 |
2021-02-22 |
Revolution Medicines Inc |
Análogos de rapamicina a c40, c28 y c32 como inhibidores de mtor
|
WO2019213611A1
(en)
|
2018-05-04 |
2019-11-07 |
Cirius Therapeutics, Inc. |
Thiazolidinedione analogs for the treatment of nafld and metabolic diseases
|
JP2021527051A
(ja)
|
2018-06-05 |
2021-10-11 |
ラプト・セラピューティクス・インコーポレイテッド |
ピラゾロ−ピリミジン−アミノ−シクロアルキル化合物及びその治療的使用
|
WO2019246513A1
(en)
|
2018-06-21 |
2019-12-26 |
Calico Life Sciences Llc |
Protein tyrosine phosphatase inhibitors and methods of use thereof
|
CA3104653A1
(en)
|
2018-06-25 |
2020-01-02 |
Amplyx Pharmaceuticals, Inc. |
Pyridine derivatives substituted by heterocyclic ring and amino group
|
WO2020041758A1
(en)
|
2018-08-24 |
2020-02-27 |
City Of Hope |
Masked cytokine conjugates
|
TWI771621B
(zh)
|
2018-10-11 |
2022-07-21 |
美商嘉來克生命科學有限責任公司 |
整合應激路徑之前藥調節劑
|
TW202035408A
(zh)
|
2018-11-01 |
2020-10-01 |
大陸商凌科藥業有限公司 |
三環janus 激酶1 抑制劑及其組合物和方法
|
JP7204005B2
(ja)
|
2019-03-14 |
2023-01-13 |
カリコ ライフ サイエンシーズ エルエルシー |
タンパク質チロシンホスファターゼ阻害物質及びその使用方法
|
AR118837A1
(es)
|
2019-04-30 |
2021-11-03 |
Calico Life Sciences Llc |
Moduladores de la vía integrada del estrés
|
EP3968979A4
(de)
|
2019-05-15 |
2023-03-01 |
Bexson Biomedical, Inc. |
Ketaminformulierung für subkutane injektion
|
US11787796B2
(en)
|
2019-09-18 |
2023-10-17 |
Takeda Pharmaceutical Company Limited |
Plasma Kallikrein inhibitors and uses thereof
|
PE20221416A1
(es)
|
2019-09-18 |
2022-09-20 |
Novartis Ag |
Proteinas de fusion nkg2d y sus usos
|
JP2022549601A
(ja)
|
2019-09-18 |
2022-11-28 |
武田薬品工業株式会社 |
ヘテロアリール血漿カリクレインインヒビター
|
AU2020383625A1
(en)
|
2019-11-13 |
2022-05-05 |
Rapt Therapeutics, Inc. |
Crystalline forms of C-C chemokine receptor type 4 antagonist and uses thereof
|
AU2020407648A1
(en)
|
2019-12-18 |
2022-06-30 |
Abbvie Inc. |
Protein tyrosine phosphatase inhibitors and methods of use thereof
|
US20230219889A1
(en)
|
2020-05-19 |
2023-07-13 |
Cybin Irl Limited |
Deuterated tryptamine derivatives and methods of use
|
WO2022038171A1
(en)
|
2020-08-18 |
2022-02-24 |
Cybin Irl Limited |
Phenethylamine derivatives, compositions, and methods of use
|
PE20231656A1
(es)
|
2020-11-02 |
2023-10-17 |
Trethera Corp |
Formas cristalinas de un inhibidor de cinasa de desoxicitidina y sus usos
|
EP4247340A1
(de)
|
2020-11-18 |
2023-09-27 |
Bexson Biomedical, Inc. |
Komplexbildnersalzformulierungen von pharmazeutischen verbindungen
|
US20240058344A1
(en)
|
2020-12-18 |
2024-02-22 |
Cornell University |
Methods of treating neurodegenerative disorders and stat3-linked cancers using suppressors of electron leak
|
US11918582B2
(en)
|
2021-03-15 |
2024-03-05 |
Rapt Therapeutics, Inc. |
Pyrazole pyrimidine compounds and uses thereof
|
CN117355521A
(zh)
|
2021-03-17 |
2024-01-05 |
武田药品工业株式会社 |
血浆激肽释放酶的杂芳基抑制剂
|
CN117355523A
(zh)
|
2021-03-17 |
2024-01-05 |
武田药品工业株式会社 |
血浆激肽释放酶的多环抑制剂
|
JP2024512497A
(ja)
|
2021-03-17 |
2024-03-19 |
武田薬品工業株式会社 |
血漿カリクレインの阻害剤
|
WO2022197756A1
(en)
|
2021-03-17 |
2022-09-22 |
Shire Human Genetic Therapies, Inc. |
Plasma kallikrein inhibitors
|
CN117396473A
(zh)
|
2021-03-17 |
2024-01-12 |
武田药品工业株式会社 |
血浆激肽释放酶的咪唑并吡啶基抑制剂
|
WO2023156453A1
(en)
|
2022-02-15 |
2023-08-24 |
Cybin Irl Limited |
Phenethylamine derivatives, compositions, and methods of use
|
WO2023156450A1
(en)
|
2022-02-15 |
2023-08-24 |
Cybin Irl Limited |
Therapeutic phenethylamine compositions and methods of use
|
WO2023196432A1
(en)
|
2022-04-06 |
2023-10-12 |
Rapt Therapeutics, Inc. |
Chemokine receptor modulators and uses thereof
|